Brad Bryan, Ph.D., an assistant professor at Texas Tech University Health Sciences Center El Paso (TTUHSC El Paso), has received a $25,000 grant from Angiosarcoma Awareness, Inc. to continue researching a new treatment for angiosarcoma, a cancer of the inner lining of blood vessels.
A recent study by Dr. Bryan’s lab demonstrated that the common heart drug propranolol is capable of halting the progression of highly lethal tumors called angiosarcomas. While the discovery was promising, “the mechanism by which this drug works is still unknown,” says
Bryan, researcher at TTUHSC El Paso’s Center of Emphasis in Cancer.
Funding from Angiosarcoma Awareness, Inc. will be used to further the knowledge of how propranolol works on the cancer.
“We are pleased to fund Dr. Brad Bryan with the Rebecca Robinson Angiosarcoma Awareness, Inc. grant to study propranolol in
angiosarcoma,” says Melissa González, president of Angiosarcoma Awareness.
“Angiosarcoma is a rare and aggressive disease with poor prognosis, and our organization strives to take steps towards funding important research to help understand what drives this malignancy, find new treatment strategies, and ultimately save the lives of patients battling this cancer.”
Dr. Bryan’s research lab will specifically study how propranolol affects angiosarcoma’s resistance to therapies, such as chemotherapy and radiation, which may be key to understanding how the drug stops the growth of the cancer.